​

Elevance Health (ELV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ELV Stock Forecast

Elevance Health (ELV) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $387.14, with a high of $425.00 and a low of $332.00. This represents a 11.19% increase from the last price of $348.18.

$300 $360 $420 $480 $540 $600 High: $425 Avg: $387.14 Low: $332 Last Closed Price: $348.18

ELV Stock Rating

Elevance Health stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 26 Buy (70.27%), 11 Hold (29.73%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 37 0 11 26 Strong Sell Sell Hold Buy Strong Buy

ELV Price Target Upside V Benchmarks

TypeNameUpside
StockElevance Health11.19%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Plans Stocks18.83%

Price Target Trends

1M3M12M
# Anlaysts111830
Avg Price Target$391.00$392.78$398.90
Last Closing Price$348.18$348.18$348.18
Upside/Downside12.30%12.81%14.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 264117--22
Jan, 26498--21
Dec, 254107--21
Nov, 254107--21
Oct, 254116--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2026RBC Capital$358.00$341.834.73%2.82%
Feb 02, 2026Truist Financial$390.00$341.2914.27%12.01%
Feb 02, 2026Craig-Hallum$409.00$340.6820.05%17.47%
Feb 01, 2026Bernstein$409.00$345.7418.30%17.47%
Jan 30, 2026Wells Fargo$391.00$346.9812.69%12.30%
Jan 30, 2026Barclays$393.00$346.9813.26%12.87%
Jan 29, 2026UBS$400.00$345.2715.85%14.88%
Jan 29, 2026Deutsche Bank$332.00$345.22-3.83%-4.65%
Jan 29, 2026Jason CassorlaGuggenheim$396.00$341.8515.84%13.73%
Jan 22, 2026Jason CassorlaGuggenheim$414.00$369.8811.93%18.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 03, 2026RBC CapitalOutperformSector Performdowngrade
Feb 01, 2026BernsteinOutperformOutperformhold
Jan 29, 2026Deutsche BankHoldHoldhold
Jan 22, 2026GuggenheimBuyBuyhold
Jan 08, 2026Wolfe ResearchOutperformupgrade
Jan 07, 2026Wells FargoOverweightOverweighthold
Jan 06, 2026BernsteinOutperformOutperformhold
Jan 05, 2026BarclaysOverweightOverweighthold
Dec 19, 2025Deutsche BankHolddowngrade
Nov 26, 2025Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$20 $29 $38 $47 $56 $65 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$25.25$24.56$25.38$25.81$25.18----
Avg Forecast$25.94$29.02$33.07$33.21$34.49$39.12$45.09$53.01$60.81
High Forecast$26.78$29.93$33.17$33.39$35.31$43.70$46.79$55.16$63.27
Low Forecast$24.92$27.99$33.01$32.43$31.08$34.75$42.00$50.33$57.73
Surprise %-2.66%-15.37%-23.25%-22.28%-26.99%----

Revenue Forecast

$100B $140B $180B $220B $260B $300B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$138.64B$156.59B$171.34B$176.81B$199.13B----
Avg Forecast$137.85B$156.30B$170.38B$175.83B$191.75B$205.47B$221.23B$241.40B$279.48B
High Forecast$141.29B$160.07B$171.02B$177.24B$196.06B$217.15B$222.36B$248.91B$288.17B
Low Forecast$133.66B$152.01B$169.32B$174.23B$183.87B$194.40B$220.09B$232.01B$268.60B
Surprise %0.57%0.19%0.56%0.56%3.85%----

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$6.10B$5.89B$5.99B$5.98B$5.66B----
Avg Forecast$5.67B$6.08B$5.99B$7.67B$7.74B$9.14B$10.35B$12.36B$14.17B
High Forecast$6.81B$7.30B$7.18B$7.78B$8.23B$10.19B$10.91B$12.86B$14.75B
Low Forecast$4.54B$4.87B$4.79B$7.56B$7.24B$8.10B$9.79B$11.73B$13.46B
Surprise %7.56%-3.08%--22.05%-26.82%----

ELV Forecast FAQ

Is Elevance Health stock a buy?

Elevance Health stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 26 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Elevance Health is a favorable investment for most analysts.

What is Elevance Health's price target?

Elevance Health's price target, set by 37 Wall Street analysts, averages $387.14 over the next 12 months. The price target range spans from $332 at the low end to $425 at the high end, suggesting a potential 11.19% change from the previous closing price of $348.18.

How does Elevance Health stock forecast compare to its benchmarks?

Elevance Health's stock forecast shows a 11.19% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the healthcare plans stocks industry (18.83%).

What is the breakdown of analyst ratings for Elevance Health over the past three months?

  • February 2026: 18.18% Strong Buy, 50.00% Buy, 31.82% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 19.05% Strong Buy, 42.86% Buy, 38.10% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 19.05% Strong Buy, 47.62% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Elevance Health’s EPS forecast?

Elevance Health's average annual EPS forecast for its fiscal year ending in December 2026 is $39.12, marking a 55.36% increase from the reported $25.18 in 2025. Estimates for the following years are $45.09 in 2027, $53.01 in 2028, and $60.81 in 2029.

What is Elevance Health’s revenue forecast?

Elevance Health's average annual revenue forecast for its fiscal year ending in December 2026 is $205.47B, reflecting a 3.18% increase from the reported $199.12B in 2025. The forecast for 2027 is $221.23B, followed by $241.4B for 2028, and $279.48B for 2029.

What is Elevance Health’s net income forecast?

Elevance Health's net income forecast for the fiscal year ending in December 2026 stands at $9.14B, representing an 61.50% increase from the reported $5.66B in 2025. Projections indicate $10.35B in 2027, $12.36B in 2028, and $14.17B in 2029.